News und Analysen
Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2023
Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Vistagen to Present at Stifel 2023 Healthcare Conference
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
ISoP New Board of Trustees Members Announced
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, announced today that Amparo de la Peña, Vice
ICON plc to Present at Upcoming Investor Conferences
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the Jefferies
Historic Victory as People With Diabetes Win Access to Life-Changing Technology, But Almost Half Don’t Understand the Benefits1-2
DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today new market research which found 79% of people struggle to
Historic Victory as People With Diabetes Win Access to Life-Changing Technology, But Almost Half Don’t Understand the Benefits1-2
DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today new market research which found 79% of people struggle to
Xencor Reports Third Quarter 2023 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today
Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the sale
Inogen Announces Third Quarter 2023 Financial Results
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September
Transgene Reports Business Update and Q3 2023 Financial Position
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update and its
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the presentation of five studies (one oral and four posters) at the annual American College of Rheumatology
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Premier, Inc. Reports Fiscal-Year 2024 First-Quarter Results
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2024 first quarter ended September 30, 2023.
"Our
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement
NanoString Technologies Releases Operating Results for Third Quarter of 2023
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
Humana Announces Four New Sponsorships of Leading U.S. Pickleball Organizations to Inspire and Promote Active and Healthy Lifestyles for All Ages, With a Special Focus on Seniors
In recognition of pickleball’s rapidly growing popularity in the U.S., the increasing need for court space across the country, and the sport’s life-changing benefits both on and off the courts
Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented data from
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the presentation of nine studies (one oral and eight posters) at the annual American Society of Nephrology
Puma Biotechnology Reports Third Quarter 2023 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2023. Unless otherwise stated, all comparisons are for
Acadia Healthcare Reports Third Quarter 2023 Results and Updates Guidance Ranges to Reflect Continued Strong Business Growth and Momentum
Acadia Healthcare Company, Inc. (“Acadia”) (NASDAQ: ACHC) today announced financial results for the third quarter ended September 30, 2023.
Third Quarter Highlights
-
Revenue totaled $750.3
ABIONYX Pharma RACERS Study Data in Sepsis Presented at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Aamir Malik, Chief Business Innovation Officer, Executive Vice President, at
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Aamir Malik, Chief Business Innovation Officer, Executive Vice President, at